Euglena Co., Ltd.
【Euglena】Q1 FY2026 Financial Results | Sales of ¥13,197 million (+10.6% YoY)
In the first quarter of the fiscal year ending December 2026, sales reached ¥13,197 million (up 10.6% YoY), operating profit was ¥837 million (up 35.4%), and net loss improved to ¥32 million. The healthcare segment performed steadily, and the consolidated subsidiaries of Q'sai Group and Satis Pharmaceutical Group contributed to the growth of adjusted EBITDA, which expanded to ¥1,821 million.
Key Figures
- Sales Revenue: ¥13,197 million (up 10.6% YoY)
- Adjusted EBITDA: ¥1,821 million (up 17.8% YoY)
- Net Income attributable to Parent Company shareholders: △¥32 million (Last year's same period: ¥△507 million)
AI要約
Performance Overview
Euglena Co., Ltd. achieved sales of ¥13,197 million (up 10.6% YoY) in the first quarter of FY2026, with adjusted EBITDA expanding to ¥1,821 million (up 17.8%). Operating profit increased significantly to ¥837 million (up 35.4%), and ordinary income rose sharply to ¥782 million (up 79.3%), maintaining profitability. The healthcare segment performed steadily, reflecting the effects of the consolidation of Q'sai Group and Satis Pharmaceutical Group subsidiaries. Net loss slightly narrowed, and the financial position remains solid.
Outlook and Impact on Shareholders
Looking ahead, the company plans to expand advertising investments and explore new markets, while advancing the commercialization of its biofuel business through the construction of a commercial plant in Malaysia. Capital policy will include share buybacks and adjustments to capital reserves to balance shareholder returns and business growth. The company aims for sustained growth and continued profitability, evolving into an attractive enterprise for investors.
Sales Revenue Trend
Operating Profit Trend
Segment Revenue Breakdown
Profit Margin Analysis
Euglena Co., Ltd.
Company overview · Stock price · Financial data · All IR
